Regenxbio, Clearside enter option and license agreement for SCS Microinjector

Regenxbio and Clearside Biomedical announced an option and license agreement that will give Regenxbio exclusive worldwide rights to Clearside’s SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space.

RGX-314 includes the NAV AAV8 vector encoding an antibody fragment to inhibit VEGF. Regenxbio is evaluating RGX-314 using the SCS Microinjector for in-office, nonsurgical delivery to the suprachoroidal space while also advancing its subretinal delivery program for the treatment of wet age-related macular degeneration and diabetic retinopathy, according to a press release.

“We are pleased to partner with Clearside in evaluating the use of the SCS Microinjector to deliver RGX-314 to the suprachoroidal space in the eye. We believe this approach can potentially allow for the treatment of an expanded population of patients with wet AMD and DR by providing access to gene therapy treatment in all settings of patient care,” Kenneth T. Mills, president and CEO of Regenxbio, said in the release. “Delivery into the suprachoroidal space, which in clinical trials has demonstrated minimal associated procedural risks, may allow physicians to treat patients with diseases like DR earlier in the disease course with RGX-314.”

Under the agreement, Regenxbio has an option to receive an exclusive worldwide commercial license, with rights to sublicense the Clearside SCS Microinjector, and Clearside will receive a fee upon the exercise of this option. Clearside will also receive up to $34 million in total development milestones, up to $102 million in sales milestones and mid-single digit royalties on net sales of products that use the microinjector, the release said.

Regenxbio and Clearside Biomedical announced an option and license agreement that will give Regenxbio exclusive worldwide rights to Clearside’s SCS Microinjector for the delivery of RGX-314 to the suprachoroidal space.

RGX-314 includes the NAV AAV8 vector encoding an antibody fragment to inhibit VEGF. Regenxbio is evaluating RGX-314 using the SCS Microinjector for in-office, nonsurgical delivery to the suprachoroidal space while also advancing its subretinal delivery program for the treatment of wet age-related macular degeneration and diabetic retinopathy, according to a press release.

“We are pleased to partner with Clearside in evaluating the use of the SCS Microinjector to deliver RGX-314 to the suprachoroidal space in the eye. We believe this approach can potentially allow for the treatment of an expanded population of patients with wet AMD and DR by providing access to gene therapy treatment in all settings of patient care,” Kenneth T. Mills, president and CEO of Regenxbio, said in the release. “Delivery into the suprachoroidal space, which in clinical trials has demonstrated minimal associated procedural risks, may allow physicians to treat patients with diseases like DR earlier in the disease course with RGX-314.”

Under the agreement, Regenxbio has an option to receive an exclusive worldwide commercial license, with rights to sublicense the Clearside SCS Microinjector, and Clearside will receive a fee upon the exercise of this option. Clearside will also receive up to $34 million in total development milestones, up to $102 million in sales milestones and mid-single digit royalties on net sales of products that use the microinjector, the release said.